Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving ...

A trial using PET scans to test the anti-inflammatory drug PIPE-791 finished enrolling healthy volunteers and patients with ...

A new study by researchers in the Department of Clinical Neuroscience, Karolinska Institutet, has identified 18 potential ...

One of the fundamental barriers to equitable neurological care is the historic male bias in clinical research. For decades, ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

When ocrelizumab became the first FDA-approved treatment for early forms of multiple sclerosis (MS) in 2017, it offered ...

The first person with multiple sclerosis was imaged in a clinical trial of a PET tracer to track myelin changes.

VANCOUVER, BC / ACCESS Newswire / July 7, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC:XPHYF)(FSE:4XT), a bioscience innovator specializing in advanced drug delivery systems ...

Former Abbott executive who led the US launch and global expansion of Humira® adds three decades of commercial and clinical leadership expertise ...

For most people with MS, a cup or two a day is fine and may even help some symptoms like fatigue and cognitive function. But ...

Illinois engineers fused ultrafast imaging with smart algorithms to peek at living brain chemistry, turning routine MRIs into ...

The American Academy of Neurology issues new guidelines to help clinicians navigate the use of unproven neurologic therapies lacking FDA approval or strong evidence.